William Blair Issues Positive Outlook for Korro Bio Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – William Blair upped their Q3 2025 EPS estimates for shares of Korro Bio in a research note issued on Tuesday, August 12th. William Blair analyst M. Minter now expects that the company will earn ($2.97) per share for the quarter, up from their prior estimate of ($3.03). The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio’s Q4 2025 earnings at ($3.00) EPS, FY2025 earnings at ($11.21) EPS, Q1 2026 earnings at ($3.06) EPS, Q2 2026 earnings at ($3.09) EPS, Q3 2026 earnings at ($3.12) EPS, Q4 2026 earnings at ($3.14) EPS, FY2026 earnings at ($12.40) EPS, FY2027 earnings at ($13.19) EPS and FY2028 earnings at ($12.55) EPS.

A number of other analysts have also commented on the stock. Cantor Fitzgerald raised shares of Korro Bio to a “strong-buy” rating in a research note on Tuesday, April 29th. Oppenheimer reduced their price objective on shares of Korro Bio from $155.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, May 13th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Korro Bio in a research note on Wednesday. Raymond James Financial reduced their price objective on shares of Korro Bio from $153.00 to $147.00 and set a “strong-buy” rating for the company in a research note on Wednesday. Finally, HC Wainwright reduced their price objective on shares of Korro Bio from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $86.83.

Korro Bio Trading Up 1.9%

KRRO stock opened at $20.26 on Friday. Korro Bio has a one year low of $10.29 and a one year high of $98.00. The firm has a market capitalization of $190.24 million, a PE ratio of -2.08 and a beta of 2.51. The firm has a 50-day moving average of $14.32 and a two-hundred day moving average of $18.02.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($2.74) EPS for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.20). The business had revenue of $1.46 million for the quarter, compared to the consensus estimate of $0.41 million.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently made changes to their positions in the business. Deep Track Capital LP increased its holdings in shares of Korro Bio by 2.9% in the 4th quarter. Deep Track Capital LP now owns 874,614 shares of the company’s stock valued at $33,297,000 after purchasing an additional 24,614 shares during the period. Driehaus Capital Management LLC increased its holdings in shares of Korro Bio by 17.7% in the 1st quarter. Driehaus Capital Management LLC now owns 582,449 shares of the company’s stock valued at $10,140,000 after purchasing an additional 87,544 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Korro Bio by 11.0% in the 4th quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company’s stock valued at $18,806,000 after purchasing an additional 49,147 shares during the period. Cormorant Asset Management LP acquired a new position in shares of Korro Bio in the 1st quarter valued at about $6,621,000. Finally, Geode Capital Management LLC increased its holdings in shares of Korro Bio by 10.8% in the 2nd quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock valued at $1,941,000 after purchasing an additional 15,166 shares during the period. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).